Published in Proc Natl Acad Sci U S A on September 23, 2009
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe (2012) 2.03
The cell biology of receptor-mediated virus entry. J Cell Biol (2011) 1.75
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci U S A (2010) 1.45
The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol (2010) 1.36
Role of phosphatidylserine receptors in enveloped virus infection. J Virol (2014) 1.10
Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. J Immunol (2011) 1.06
Poxvirus cell entry: how many proteins does it take? Viruses (2012) 1.05
Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J (2011) 1.04
Differential innate immune signaling in macrophages by wild type vaccinia mature virus and a mutant virus deleting A26 protein. J Virol (2017) 1.03
Vaccinia virus A25 and A26 proteins are fusion suppressors for mature virions and determine strain-specific virus entry pathways into HeLa, CHO-K1, and L cells. J Virol (2010) 1.03
Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology (2010) 0.93
Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology (2014) 0.93
Direct formation of vaccinia virus membranes from the endoplasmic reticulum in the absence of the newly characterized L2-interacting protein A30.5. J Virol (2013) 0.90
Surfactant and its role in the pathobiology of pulmonary infection. Microbes Infect (2011) 0.88
Lipid membranes in poxvirus replication. Viruses (2010) 0.88
Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses. Viruses (2015) 0.84
Phosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function. Parasite Immunol (2013) 0.84
Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH. J Virol (2012) 0.84
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82
Fine structure of the vaccinia virion determined by controlled degradation and immunolocalization. Virology (2014) 0.81
Membrane fusion during poxvirus entry. Semin Cell Dev Biol (2016) 0.81
Surfactant Lipids at the Host-Environment Interface. Metabolic Sensors, Suppressors, and Effectors of Inflammatory Lung Disease. Am J Respir Cell Mol Biol (2016) 0.79
Intracellular Transport of Vaccinia Virus in HeLa Cells Requires WASH-VPEF/FAM21-Retromer Complexes and Recycling Molecules Rab11 and Rab22. J Virol (2015) 0.79
Lipid interactions during virus entry and infection. Cell Microbiol (2014) 0.78
Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes. J Invest Dermatol (2014) 0.76
Leishmania amazonensis exhibits phosphatidylserine-dependent procoagulant activity, a process that is counteracted by sandfly saliva. Mem Inst Oswaldo Cruz (2013) 0.75
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma. Mol Ther Oncolytics (2017) 0.75
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol (1992) 11.24
Identification of Tim4 as a phosphatidylserine receptor. Nature (2007) 6.06
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science (2008) 5.04
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature (2007) 4.36
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Virus entry by macropinocytosis. Nat Cell Biol (2009) 3.87
Clearance of apoptotic cells: getting rid of the corpses. Mol Cell (2004) 3.64
Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J (1993) 3.41
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res (2006) 3.17
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol (1998) 2.97
A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology (1995) 2.82
Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles. J Gen Virol (1976) 2.78
Poxvirus entry and membrane fusion. Virology (2006) 2.69
Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol (2000) 2.60
Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ (2007) 2.44
Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol (1999) 2.43
Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV. Mol Biol Cell (2000) 2.16
Studies on the nature and location of the capsid polypeptides of vaccinia virions. Virology (1972) 2.11
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res (2002) 2.02
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
Neutralizing epitope on penetration protein of vaccinia virus. Virology (1996) 1.75
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol (2005) 1.70
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc Natl Acad Sci U S A (2006) 1.62
Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin. J Virol (2006) 1.52
The envelope G3L protein is essential for entry of vaccinia virus into host cells. J Virol (2006) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis. J Virol (2008) 1.41
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry. J Virol (2008) 1.20
Two distinct low-pH steps promote entry of vaccinia virus. J Virol (2007) 1.13
The envelope of vaccinia virus reveals an unusual phospholipid in Golgi complex membranes. J Cell Sci (1996) 1.03
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology (2007) 1.00
Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology (2009) 0.99
The activation of vaccinia virus infectivity by the transfer of phosphatidylserine from the plasma membrane. Virology (1983) 0.96
Phospholipid determinants for annexin V binding sites and the role of tryptophan 187. Biochemistry (1994) 0.89
Reversible inactivation and reactivation of vaccinia virus by manipulation of viral lipid composition. Virology (1985) 0.87
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol (2006) 1.40
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol (2007) 1.40
Vaccinia virus G7L protein Interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J Virol (2003) 1.39
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J Virol (2005) 1.39
Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc Natl Acad Sci U S A (2007) 1.38
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc Natl Acad Sci U S A (2003) 1.28
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol (2009) 1.27
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.24
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23
Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane. Proc Natl Acad Sci U S A (2006) 1.23
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol (2006) 1.22
Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses. J Virol (2007) 1.22
Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology (2004) 1.21
Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology (2002) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Expression profiling of the intermediate and late stages of poxvirus replication. J Virol (2011) 1.20
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts. J Virol (2011) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol (2002) 1.18
Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol (2009) 1.16
Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol (2002) 1.16
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (2007) 1.16
Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe (2012) 1.15
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J Virol (2002) 1.14
Assembly and disassembly of the capsid-like external scaffold of immature virions during vaccinia virus morphogenesis. J Virol (2009) 1.14
Poxvirus DNA primase. Proc Natl Acad Sci U S A (2007) 1.14
Evidence for an essential catalytic role of the F10 protein kinase in vaccinia virus morphogenesis. J Virol (2004) 1.13
Two distinct low-pH steps promote entry of vaccinia virus. J Virol (2007) 1.13
Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol (2010) 1.13
Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology (2006) 1.12
Vaccinia virus A36R membrane protein provides a direct link between intracellular enveloped virions and the microtubule motor kinesin. J Virol (2004) 1.12
Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med (2008) 1.11
A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. Virology (2008) 1.10
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology (2007) 1.09
Physical and functional interactions between vaccinia virus F10 protein kinase and virion assembly proteins A30 and G7. J Virol (2004) 1.08
A complex of seven vaccinia virus proteins conserved in all chordopoxviruses is required for the association of membranes and viroplasm to form immature virions. Virology (2004) 1.08
Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J Virol (2008) 1.07
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol (2010) 1.07
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses (2007) 1.07